Similar Search Results

Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

Erder, M.; Xie, Jipan; Signorovitch, James; Chen, Kristina - In: Applied Health Economics and Health Policy 11 (2013) 3, pp. 309-309

Persistent link: https://www.econbiz.de/10010848781

Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

Erder, M.; Xie, Jipan; Signorovitch, James; Chen, Kristina - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 381-395

<Emphasis Type="Bold">Background: About 7% of children and adolescents are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in the US. Patients with ADHD who are intolerant of or do not have an optimal response to stimulants often use non-stimulants as alternative therapies. Guanfacine extendedrelease...</emphasis>

Persistent link: https://www.econbiz.de/10011000747

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application...

Erder, M.; Xie, Jipan; Signorovitch, James; Chen, Kristina - In: Applied Health Economics and Health Policy 11 (2013) 3, pp. 307-307

Persistent link: https://www.econbiz.de/10011000750